Evidence map›Paper›PMID 37193135›Full record

ArticleAmerican journal of translational research2023

CXCL5 knockdown attenuated gemcitabine resistance of pancreatic cancer through regulation of cancer cells and tumour stroma.

Nien-Hung Lee, Yi Ma, Ching-Seng Ang, Chelsea Dumesny, Nhi Huynh, Yang Yang, Kai Wang, Mehrdad Nikfarjam, Hong He

Open access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in American journal of translational research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Nien-Hung LeeDepartment of Surgery, University of Melbourne, Austin Health Heidelberg, Victoria, Australia.
Yi MaDepartment of Surgery, University of Melbourne, Austin Health Heidelberg, Victoria, Australia.
Ching-Seng AngBio-21 Institute, University of Melbourne Parkville, Victoria, Australia.
Chelsea DumesnyDepartment of Surgery, University of Melbourne, Austin Health Heidelberg, Victoria, Australia.
Nhi HuynhDepartment of Surgery, University of Melbourne, Austin Health Heidelberg, Victoria, Australia.
Yang YangDepartment of Surgery, University of Melbourne, Austin Health Heidelberg, Victoria, Australia.
Kai WangDepartment of Surgery, University of Melbourne, Austin Health Heidelberg, Victoria, Australia.
Mehrdad NikfarjamDepartment of Surgery, University of Melbourne, Austin Health Heidelberg, Victoria, Australia.
Hong HeDepartment of Surgery, University of Melbourne, Austin Health Heidelberg, Victoria, Australia.
Austin Health · AULudwig Cancer Research · AUThe University of Melbourne · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chemoresistance is one of the major causes to the poor prognosis of pancreatic cancer (PC). Gemcitabine alone and gemcitabine-based therapies are mostly used for the treatment of PC. Gemcitabine resistance becomes the focus of chemotherapy. C-X-C motif chemokine 5 (CXCL5), a member of the C-X-C chemokine family, acts through C-X-C chemokine receptor type 2 (CXCR2). A high level of CXCL5 is associated with worse prognosis in PC patients and increased suppressive immune cell infiltration. Increased expression of CXCL5 is also found in gemcitabine-treated PC cells. To investigate the role of CXCL5 in PC response to gemcitabine, CXCL5 knockdown (KD) PC cells were generated and its effect on cancer cell response to gemcitabine

Indexed as

collagen ICXCR2CXL5gemcitabinetumour stromaα-SMA

Identifiers

PMID37193135
PMCPMC10182491
OpenAlexW4376871506

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.